Cannabis Science Inc., (CBIS) on Friday, July 20th Robert Melamede PhD, CEO of Cannabis Science presented at the Treatment Horizons Briefing at the Rayburn Legislative Office Building in Washington D.C, sponsored by Rep. Danny Davis (D-IL) and Rep Bobby Rush (D-IL) for an audience of congressional staffers on the utility of CS-TATI-1, a unique antiviral approach to reduce the expression of viral diversity undermining the efficacy of HART through out global treatment programs.

Dr. Melamede states, “Cannabis Science is very appreciative of the opportunity to present the clinical premise supporting the development of CS-TATI-1 to address the application of CNR1 and CNR2 agonists and antagonists of HIV Tat expression inhibitors to legislative staffers of ranking Members of Congress directly preceding the opening of the XIX International AIDS Conference,” said Dr. Melamede. “The clinical advancement of the indirect inhibition of HIV Tat and subsequent corresponding pandemic co-infections that promote the oncogenesis of HIV related malignancies is essential to avert the pathogenesis of minority subspecies from highly conserved sanctuary regions.”

“It's a very important for the further development of CS-TATI-1 to provoke legislative interest in CS-TATI-1 to ensure federal facilitation of further development of the clinical advancement of research necessary for the commercialization of CNR1 and CNR2 agonists and antagonists of HIV Tat expression inhibitors,” said Mariel Selbovitz, MPH. VP of Research Program Development at Cannabis Science. “Providing this essential clinical briefing to Congressional staffers at the World AIDS Institute legislative briefing has afforded Cannabis Science the opportunity to obtain support for a federal initiative that will advance CS-TATI-1 to first human dosing.”

About CS-TAT-1

Data published in March by researchers at the Mount Sinai School of Medicine found that phytocannabinoids inhibit TAT induced migration to TAT via CNR2 signal transduction. Funding for the Mount Sinai study was provided by a National Institutes of Health (NIH) Clinical and Translational Science Award Grant. Cannabis Science’s research of CS-TATI-1 will be targeted to newly diagnosed patients infected with drug resistant virus, treatment experienced patients with drug-resistant HIV strains, and those intolerant of currently available therapies. Cannabis Science will be pursuing a wide range of NIH based Federal Research Programs such as RO1’s, PO1’s and SBIRS which exist to support preclinical development of target validation and proof of concept studies. These studies will be implemented through collaborations with leading scientific institutions. Cannabis Science will also be pursuing other clinical research collaborations including the AIDS Clinical Trials Groups (ACTG), the Canadian AIDS Trial Network (CATN) and the European AIDS Trial Network (EATN).

About HIV

HIV’s ability to mutate and reproduce itself even in the presence of antiretroviral drugs, has led to a growing rate of drug resistance. Increasing drug resistance is severely limiting treatment options for HIV patients around the world, increasing direct and indirect health costs, furthering the spread of drug resistant strains of HIV and is creating a pressing need to develop new HIV drugs.

The U.S. government invests billions of dollars a year in HIV/AIDS research, treatment and care through a variety of programs. The Ryan White CARE Act, which funds the treatment and care of people living with HIV in the U.S., totals $2.3 billion a year. Among its many other contributions to fighting HIV/AIDS globally, the U.S. provides $22.8 million annually to The U.S. Military HIV Research Program and approximately $1 billion per year to The Global Fund to Fight AIDS, Tuberculosis and Malaria.

Pharmaceutical sales to treat HIV equal $10.6 billion annually. Treatment cost per patient in the U.S. for HIV antivirals alone is approximately $15,000 a year.

About the XIX International AIDS Conference

The XIX International AIDS Conference is taking place July 22-27, 2012 in Washington, DC. Bringing together leading researchers, clinicians, policy makers and advocates, this momentous conference presents and affords discussion on the latest scientific advances in HIV/AIDS.

About The World AIDS Institute

The World AIDS Institute documents and preserves the global history of HIV/AIDS, inspires action today to improve the lives of people living with HIV and their families, friends and communities, and strengthens the spectrum of innovative initiatives to find a cure.

About Cannabis Science, Inc.

Cannabis Science, Inc. is conducting cannabinoid research and development for unmet medical needs. The Company works with leading experts in HIV drug development, medicinal characterization, and clinical research to develop, produce, and commercialize Phytocannabinoid-based pharmaceutical products.

Cannabis Science is currently working with CBR International to develop a Pre-IND Application to the FDA that focuses on the use of CS-S/BCC-1 topical cannabis-based preparations for the treatment of basal and squamous cell carcinomas.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.